In a report released on August 9, Research Report). The company’s shares closed yesterday at $44.10.
Risinger covers the Healthcare sector, focusing on stocks such as Pfizer, Sanofi, and Eli Lilly & Co. According to TipRanks, Risinger has an average return of 3.2% and a 47.62% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Halozyme with a $54.00 average price target, implying a 22.45% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $60.00 price target.
HALO market cap is currently $5.98B and has a P/E ratio of 17.16.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Read More on HALO:
- SVB Securities Reaffirms Their Hold Rating on Waters (WAT)
- Cogent Biosciences (COGT) Receives a Buy from SVB Securities
- Pliant Therapeutics (PLRX) Receives a Buy from SVB Securities
- SVB Securities Sticks to Their Hold Rating for Amgen (AMGN)
- SVB Securities Reaffirms Their Hold Rating on Enanta Pharmaceuticals (ENTA)